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Extracorporeal delivery of a 
therapeutic enzyme
Chun Zhang1,*, Jun Pu2,*, Xiaolan Yang1,*, Tao Feng1, Fang Liu1, Deqiang Wang1, Xiaolei Hu1, 
Ang Gao1, Hongbo Liu1, Chang-Guo Zhan3 & Fei Liao1
To remove circulating harmful small biochemical(s)/substrates causing/deteriorating certain chronic 
disease, therapeutic enzyme(s) delivered via vein injection/infusion suffer(s) from immunoresponse 
after repeated administration at proper intervals for a long time and short half-lives since delivery. 
Accordingly, a novel, generally-applicable extracorporeal delivery of a therapeutic enzyme is proposed, 
by refitting a conventional hemodialysis device bearing a dialyzer, two pumps and connecting tubes, 
to build a routine extracorporeal blood circuit but a minimal dialysate circuit closed to circulate the 
therapeutic enzyme in dialysate. A special quantitative index was derived to reflect pharmacological 
action and thus pharmacodynamics of the delivered enzyme. With hyperuricemic blood in vitro and 
hyperuricemic geese, a native uricase via extracorporeal delivery was active in the dialysate for periods 
much longer than that in vivo through vein injection, and exhibited the expected pharmacodynamics 
to remove uric acid in hyperuricemic blood in vitro and multiple forms of uric acid in hyperuricemic 
geese. Therefore, the extracorporeal delivery approach of therapeutic enzymes was effective to remove 
unwanted circulating small biochemical(s)/substrates, and was expected to avoid immunogenicity 
problems of therapeutic enzymes after repeated administration at proper intervals for a long time due 
to no contacts with macromolecules and cells in the body.
Certain chronic disease, such as chronic kidney failure or metabolic deficiency/disorder, is caused and/or dete-
riorated by harmful small biochemical(s) in blood. The treatment of such a chronic disease requires removal of 
the circulating harmful small biochemical(s), mainly by repeated administration of hemodialysis or therapeutic 
enzyme(s)1–4. However, hemodialysis is limited by dialysis disequilibrium syndrome and the imbalance of small 
nutrients/hormones. Therapeutic enzymes may be delivered via vein infusion or injection, but suffer from short 
circulation half-lives since delivery and immunogenicity after repeated administration at proper intervals for a 
long time. For example, gout as a chronic disease is caused and deteriorated by blood uric acid at elevated levels; a 
therapy to reduce blood uric acid levels is required for gout treatment5,6. Specially, refractory gout is a major med-
ical challenge since conventional chemical agents are ineffective or intolerable, and enzyme therapy with uricase 
is the only effective treatment to date7–10. Currently, pegloticase (a formulated uricase) via vein infusion is initially 
effective in treatment of refractory gout, but its repeated use biweekly over three months ultimately elicits immu-
noresponse in most patients to greatly shorten its half-life in blood since delivery, and thus mitigate its therapeutic 
safety and efficacy8–10. To solve the immunogenicity problem, there must be an engineered/formulated enzyme of 
negligible immunogenicity, or the enzyme should be delivered via a novel approach that can avoid the immuno-
response of patients after repeated administration at proper intervals for a long time. Molecular engineering and/or 
formulation of a therapeutic enzyme to solve its immunogenicity problem remains to be a grand challenge. To 
employ an enzyme for repeated treatment of a chronic disease at proper intervals over a long time, it is thus highly 
desired to develop a novel delivery approach that can avoid the immunogenicity problem.
Conventional delivery of a therapeutic enzyme includes vein infusion, or injection through vein, muscle or 
skin, and ultimately leads to the therapeutic enzyme circulating in blood. Generally speaking, of a therapeutic 
enzyme through the conventional delivery, the immunogenicity after repeated administration at proper intervals 
for a long time and short circulation half-life since every delivery are the two principal problems, and caused 
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primarily by the interactions of the therapeutic enzyme with cells and proteins in the body. When a small sub-
strate is separated from cells and proteins in blood using a medical device and only the isolated small substrate is 
accessible to a therapeutic enzyme in the device, the blood cells and proteins in the body will not contact the ther-
apeutic enzyme and, therefore, there will be no immunoresponse at all even after repeated administration of the 
enzyme at proper intervals for a long time. For the required separation, a conventional hemodialysis system can 
be employed technically, whose basic configuration includes a dialyzer, two pumps and connecting tubes to form 
an extracorporeal blood circuit and a dialysate circuit. When the dialysate circuit is closed to circulate a small 
volume of dialysis solution containing the therapeutic enzyme, the modified hemodialysis system becomes the 
device for the desired extracorporeal delivery of the therapeutic enzyme (which is uricase in this study) (Fig. 1). 
Putatively, hemodialysis system can be repeatedly administrated at proper intervals to patients for years. A native 
uricase, which is known to elicit strong immunoresponse when repeatedly administrated at proper intervals for 
a long time via conventional delivery, is thus expected to be applicable through extracorporeal delivery for the 
continued treatment of refractory gout at no cost of immunoresponse. Moreover, since every extracorporeal 
delivery, a therapeutic enzyme in the delivery device is expected to be active for a long period determined only 
by its stability in the dialysate because there is no elimination of the therapeutic enzyme by any factors from the 
delivery device at all. Clearly, the pharmacological efficacy of a therapeutic enzyme via extracorporeal delivery 
is the first of all. Herein, the pharmacological efficacy of the extracorporeal delivery approach was investigated 
and proved with a native uricase to remove uric acid in hyperuricemic blood in vitro and hyperuricemic geese.
Results
An extracorporeal delivery device and the experimental system. In this proof-of-principle study, 
the pharmacological action of a native uricase via the extracorporeal delivery to remove blood uric acid was 
tested by using hyperuricemia models in vitro and in vivo. The proposed extracorporeal delivery device employed 
licensed DTB-100 multiple-function pumps of Chongqing Duotai Medical Equipment Co. Ltd. (China, http://
www.cqduotai.com/showimg.asp?id= 6&foid= 10), licensed UT-300S dialyzer from Nippro Medical Equipment 
Co. Ltd (Shanghai, China; http://www.nipro-trading.com.cn/), and dedicated sterile connecting tubes from 
Jiangxi Sanxin Medical Equipment Co. Ltd. (Jiangxi; http://www.sanxin-med.com/). To facilitate sampling, injec-
tion interfaces made from latexes were inserted at 2.0 cm before and after the dialyzer in the connecting tubes of 
the blood circuit, and at somewhere of the dialysate circuit. The volume of blood in the dialyzer and the connect-
ing tubes reached 28 ml, which affected the selection of hyperuricemia model in vivo.
Figure 1. Work principle of the extracorporeal delivery device. 
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A recombinant bacterial uricase was prepared and its native form was directly used11,12. A hyperuricemia 
model in vivo can be developed with a potent inhibitor against the endogenous uricase of a laboratory animal. 
However, there are no steady levels of blood uric acid for a long time with such a hyperuricemia model, due to the 
metabolism of both the inhibitor and uric acid; this fact inevitably requires more experimental efforts to charac-
terize the pharmacological action of the delivered uricase. Additionally, any inhibitor in blood will diffuse into the 
dialysate to interfere with the action of the delivered uricase, and thus complicate the pharmacodynamics of the 
delivered uricase. Fortunately, some avian animals lack uricase and have inherent hyperuricemia13. The volume of 
blood in the dialyzer and the connecting tubes indicated the need of a hyperuricemic animal model bearing total 
blood capacity over 300 ml since less than 10% of the total amount of blood in the body can be circulated extracor-
poreally. The total amount of blood (in liter) of an animal is usually assumed to be 6% of its body weight (in kg). 
Grown-up goose of body weight over 5.0 kg was thus the suitable hyperuricemia model in vivo for favorable 
cost13. Fresh goose blood sample of 200 ml was utilized as the hyperuricemia model in vitro. The extracorporeal 
circulation speed of blood was fixed at 15 ml/min, due to the limited tolerability of goose.
Quantitative characterization of the pharmacological action of the delivered uricase. For 
extracorporeal delivery of anyone enzyme to remove its diffusible small substrate in blood in vitro or in vivo, the 
dynamic change of the total quantity of the small substrate in the experimental system reflects the pharmacody-
namics. Consequently, the quantity of the small substrate eliminated from the experimental system within a short 
sampling interval during the continued action of the enzyme delivered in the device (SQi) reflects the instanta-
neous pharmacological action; the sum of SQi over the continued action periods started from the same initial 
sampling timepoint indexes pharmacodynamics for enzymatic removal of the small substrate in blood. Clearly, 
transmembrane diffusion of the small substrate from blood into the dialysate is the prerequisite for its removal 
by the delivered enzyme. To simplify pharmacodynamics, the enzyme was added into the closed dialysate circuit 
after the equilibrium of its small substrate in the two circuits, and the device plus the enzyme was continuously 
running in a reasonable period for consistent permeability of the dialyzer. To facilitate dissolution of any small 
biochemicals in the dialysate, bovine serum albumin was added to the dialysate for a concentration consistent 
with that in plasma14. Moreover, there may be the deposit of the small substrate in the dialysate; the quantity of 
the small substrate deposited in the dialysate over a given period was calculated as the capacity of the dialysate 
circuit times the change of the levels of the small substrate in the dialysate within the action period. Furthermore, 
a small substrate may be deposited in non-blood tissues and transported into blood when its level in blood is 
significantly reduced. To quantitatively characterize the pharmacological action of the delivered enzyme after 
a given continued action period, SQ1i and SQ2i were thus utilized for applicability to different situations and 
estimated as follows.
SQ1i considered the distribution of the small substrate in different tissues and the transportation of the small 
substrate from non-blood tissues into blood, which was discussed in detail with uric acid in goose as the example. 
Putatively, only free molecules of uric acid can diffuse across the dialyzer. However, free molecules, precipitates, 
soluble and insoluble complexes of uric acid are found in goose tissues13, and have different rates to be transported 
into the dialysate. Based on transportation kinetics, uric acid related to uricase action in the device was classified 
into the fast-diffusing and slow-diffusing forms. The fast-diffusing uric acid included free molecules and soluble 
complexes that exist only in the dialysate (compartment A) and the plasma (compartment B); there was rapid 
equilibrium among fast-diffusing uric acid in such two compartments when both blood and dialysate were cir-
culating at proper speeds and the dialyzer membrane had sufficient permeability to uric acid. The slow-diffusing 
uric acid included precipitates and insoluble complexes that may exist in any tissues including blood itself, plus 
free molecules and soluble complexes inside cells; such localizations of slow-diffusing uric acid were assigned to 
compartment C and the transportation of uric acid from compartment C into dialysate required a much longer 
time. Clearly, the pharmacological action of the delivered uricase will remove uric acid in those three compart-
ments through transportation of uric acid among tissues. However, the quantitative processing of such transpor-
tation of uric acid among tissues was quite challenging. Fortunately, it is the diffusion of uric acid from plasma 
into the dialysate that reduces uric acid concentration in blood right after the dialyzer against that right before 
the dialyzer. To reflect pharmacodynamics after a given continued action period of the delivered uricase with the 
same initial sampling timepoint, SQ1i was estimated by numerical integration of the dynamic quantity of uric acid 
transported from plasma into the dialysate over the action period, subtracting the quantity of uric acid deposited 
in the dialysate within the same period. SQ1i utilized just the physical principle of dialysis and was thus generally 
applicable regardless of the transportation of the small substrate among tissues.
SQ2i considered no transportation of the small substrate from non-blood tissues into blood. SQ2i was calcu-
lated as the total blood capacity times the reduction of the level of the small substrate in blood right before the 
dialyzer against its initial value, subtracting the quantity of uric acid deposited in the dialysate within the same 
action period (Supplementary Note S1). To reflect pharmacodynamics of the delivered enzyme, clearly, the calcu-
lation of SQ2i was much simpler than that of SQ1i, but SQ2i was limited to anyone small substrate in blood as the 
target exhibiting no transportation among tissues.
In practice, when three series of the concentrations of fast-diffusing uric acid, in blood right before and after 
the dialyzer, and in the dialysate, were determined with a special sampling order, SQ1i and SQ2i were accessible 
concomitantly (Supplementary Note S1). Notably, SQ1i was valid but SQ2i was invalid to reflect pharmacodynam-
ics for the removal of blood uric acid by the action of the delivered uricase, when there was the transportation 
of uric acid from compartment C into compartment B. According to those definitions, the initial rate for the 
increase of valid SQ1i or SQ2i was an equivalent of the maximum SQi, and thus depended on uricase dose when 
there was the rapid equilibrium among fast-diffusing uric acid in compartment A and B. Clearly, the limitation 
on transmembrane diffusion rate of uric acid into the dialysate before uricase action supported the saturable 
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pharmacological action of the delivered uricase; the total quantity of multiple forms of diffusible uric acid was a 
determinant of the maximum of the pharmacodynamics for the removal of blood uric acid.
The removal of slow-diffusing uric acid in compartment C with hyperuricemic animal models by the deliv-
ered uricase was a marvelous advantage, and was detected by the following approach. The initial total quantity of 
fast-diffusing uric acid in plasma (TQ) was derived from its concentration before enzyme action and the sum of 
the total blood capacity plus 10 ml dialysis solution from the closed dialysate circuit (Supplementary Data S1 and 
Data S2). TQ thus considered only fast-diffusing uric acid pre-existed in blood and the dialysate before the action 
of uricase. In theory, after both the activity and action period of the delivered uricase were optimized to exhaust 
fast-diffusing uric acid originally found in the plasma before the action of the delivered uricase, the maximum 
SQ1i was limited by TQ when slow-diffusing uric acid in compartment C was not involved, but higher than TQ 
when slow-diffusing uric acid in compartment C was involved. To detect the removal of slow-diffusing uric acid in 
compartment C, thus, the ratio of the maximum SQ1i under such optimized conditions to TQ served as the index 
for comparison against a cutoff developed with reference system bearing no slow-diffusing uric acid and thus no 
transportation of uric acid among tissues. There was negligible slow-diffusing uric acid in blood in vitro when 
there were no precipitates of uric acid, since uric acid inside blood cells was negligible. Blood in vitro with uric acid 
level below the sum of its solubility limit and albumin binding capacity was suitable reference blood. Ovalbumin 
in goose blood is about 0.40 mM14; the dissociation constant of uric acid from albumin is about 20 μ M15. 
Goose blood in vitro with 0.40 to 0.80 mM uric acid thus served as reference blood to develop the cutoff for 
comparison.
Pharmacological efficacy in vitro of the delivered uricase. The hyperuricemia model in vitro with 
fresh goose blood bearing 0.40 to 0.80 mM uric acid was tested at first. During continuous running of the device 
minus uricase, uric acid concentrations in the two circuits of the delivery device reached equilibrium in 30 min 
and remained consistent in 6.0 h (Supplementary Data S3). After 6.0 h since vein injection, less than 20% activity 
of the native uricase was reserved in blood in vivo16–18. In the closed dialysate circuit, activities of the native uri-
case remained consistent in 6.0 h (Supplementary Data S3), supporting robust pharmacokinetics of the uricase 
via extracorporeal delivery.
At 0.30 U uricase, the three concentrations of uric acid continuously decreased in 3.3 h, with both faster rates 
and larger differences among them at the beginning stage, while slower rates at the later stage till their consistent 
bottoms below the quantification limit (Fig. 2a). Interestingly, SQ1i continuously increased in a saturable manner 
till its plateau as the maximum, and correlated well with SQ2i (Fig. 2b). Notably, the initial rate for the increase of 
SQ1i or SQ2i at 0.30 U uricase was smaller than that at 0.75 U uricase (Table 1; Supplementary Data S1 and Data S4), 
supporting the dose-dependent pharmacological action of the delivered uricase due to the rapid equilibrium of 
fast-diffusing uric acid in compartment A and B besides the validity of both SQ1i and SQ2i. Hence, the delivered 
uricase was pharmacologically effective to remove uric acid in hyperuricemic blood in vitro, as reflected by the 
dynamic changes of both SQ1i and SQ2i.
Pharmacological efficacy in vivo of the delivered uricase with geese as model. Continuous run-
ning of the device minus uricase led to the equilibrium of uric acid in the two circuits after 50 min and consistent 
uric acid levels in 6.0 h (Supplementary Data S5), supporting the advantage to employ goose as hyperuricemia 
model in vivo since the control experiments were rather simple. However, there was about 30% decrease of uri-
case activity after continuous running of the device for 6.0 h (Supplementary Data S5); such a decrease was much 
smaller than that of the native uricase after circulation for 6.0 h in vivo through vein injection14–16, and may be 
due to the inactivation by reactive substances originated from the interactions of transitional metal ions with the 
excessive product hydrogen peroxide19.
With 0.75 U uricase, uric acid concentrations in blood before the dialyzer showed weaker decreases than those 
with blood in vitro, but the difference in uric acid levels right before and after the dialyzer was much larger than 
the equivalent with blood in vitro (Figs 2a and 3a). Unexpectedly, there were always negligible changes of SQ2i 
versus action periods of the delivered uricase to support the invalidity of SQ2i as the pharmacodynamics index; 
sometimes, there were even the increases of uric acid levels in blood versus action periods of the delivered uri-
case to qualitatively support the invalidity of SQ2i as the index of pharmacodynamics (Fig. 3a,b; Supplementary 
Data S2). As expected, however, SQ1i always continuously and almost linearly increased in 6.0 h, regardless of 
the change patterns of blood uric acid levels (Fig. 3b). After the action of the delivered uricase for 3.3 or 6.0 h, 
the maximum SQ1i with blood in vivo still showed no association with uricase doses (Supplementary Data S4). 
However, the initial increase rate of SQ1i at 1.5 U uricase was higher than that at 0.75 uricase, but consistent with 
that at 2.3 U uricase (Table 1), supporting dose-dependent and saturable pharmacological action of the delivered 
uricase. Therefore, the delivered uricase was effective to remove blood uric acid with hyperuricemia model in vivo, 
as reflected by the dynamic change of SQ1i, rather than that of SQ2i.
Removal of multiple forms of uric acid in vivo. From the data with hyperuricemic blood in vitro bearing 
0.40 to 0.80 mM uric acid, the ratio of the maximum SQ1i for the exhaustion of fast-diffusing uric acid in blood 
to TQ was (0.96 ± 0.15) (n = 11), supporting negligible slow-diffusing uric acid in samples (Fig. 2b). At 99% 
confidence limit, the cutoff of the ratio of the maximum SQ1i to TQ was about 1.37 with reference blood; the 
total blood capacity may reach 8% of body weight, giving a cutoff of 1.66 at 99% confidence limit to recognize 
the removal of slow-diffusing uric acid in compartment C with hyperuricemic geese (Supplementary Data S4).
With goose as hyperuricemic model in vivo, uricase doses were no less than 0.75 U and the action period was 
6.0 h to facilitate exhausting fast-diffusing uric acid originally found in blood before uricase action (Table 1). 
In this case, the ratio of the maximum SQ1i to TQ was (2.5 ± 0.7) (n = 15) after uricase action for 3.3 h, and 
(4.5 ± 1.3) (n = 15) after uricase action for 6.0 h. With data after uricase action for 3.3 h, the use of the cutoff of 
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1.37 found 14 samples whose slow-diffusing uric acid in compartment C was removed while the use of the cutoff 
of 1.66 found 13 samples involving the removal of slow-diffusing uric acid. With data after uricase action for 6.0 h, 
the use of the cutoff of 1.66 still found all the samples involving the removal of slow-diffusing uric acid. Therefore, 
the delivered uricase favorably and effectively removed multiple forms of uric acid with hyperuricemia model 
in vivo, as reflected by the ratio of the maximum SQ1i to TQ after enzyme action for a sufficient period.
Figure 2. Changes of uric acid in hyperuricemia blood model in vitro and uricase pharmacodynamics. C1T,i: 
the concentration of uric acid in blood right before the dialyzer; C2T,i: the concentration of uric acid in blood 
right after the dialyzer; C3T,i: the concentration of uric acid in the closed dialysate circuit. Data processing details 




dose (U) TQa (μ mole)
Ratio of maxSQ1i 
to TQ (3.3 h)
Ratio of maxSQ1i to 
TQ (6.0 h)
Initial rate for SQ1i 
(μ mole/min)
In vitro 0.30 (6) 103 ± 19 0.88 ± 0.16 ND 0.78 ± 0.12
In vitro 0.75 (5) 155 ± 40 1.03 ± 0.18 ND 1.4 ± 0.3b
In vivo 0.75 (5) 136 ± 23 2.2 ± 0.7c 3.8 ± 1.2c 1.4 ± 0.4d
In vivo 1.5 (5) 203 ± 50 2.6 ± 0.9c 4.5 ± 1.6c 2.4 ± 0.8e
In vivo 2.3 (5) 153 ± 27 2.8 ± 0.3c 5.0 ± 0.6c 2.2 ± 0.5e
Table 1. Comparison of pharmacological action of the delivered uricase with hyperuricemic blood models 
in vitro and in vivo. ND: not determined; maxSQ1i: the maximum SQ1i after uricase action for the indicated 
period. aindicates the total blood capacity of 210 ml with hyperuricemia models in vitro and of 310 ml with 
models in vivo; bindicates P < 0.005 versus that with 0.3 U uricase in vitro; cindicates P < 0.001 versus all the data 
in vitro including those with 0.3 and 0.75 U uricase after the action for 3.3 h; dindicates P < 0.02 versus that with 
0.30 U uricase in vitro while P > 0.9 versus that with 0.75 U uricase in vitro; eindicates P < 0.05 versus that with 
0.75 U uricase in vivo, and versus that with 0.75 U or 0.30 U uricase in vitro.
www.nature.com/scientificreports/
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Discussion
Through the extracorporeal delivery approach, the applicability of a native enzyme with an ideal action period 
since every delivery, and no immunoresponse even after repeated administration at proper intervals for a long 
time, are the greatest advantages. To remove the unwanted circulating small biochemicals as substrates with 
enzymes, therapeutic efficacy and safety are the primary concerns. Therapeutic efficacy of an enzyme requires 
its bioavailability, accessibility to the small substrate in blood and a long action period since every delivery. The 
conventional delivery approach employs vein infusion or injection through certain tissue to drive the enzyme to 
where the small substrate localizes, but the extracorporeal delivery approach utilizes semi-permeable dialyzer to 
selectively drive the small substrate to where the therapeutic enzyme localizes as long as the dialyzer has sufficient 
permeability. Both delivery approaches thus provide the required bioavailability and accessibility of the enzyme 
to its small substrate. Therapeutic safety requires nontoxic enzyme product(s), negligible removal of small nutri-
ents/hormones, and negligible immunoresponse to the enzyme after repeated administration at proper intervals 
for a long time. The toxicity of product(s) and the removal of small nutrients/hormones by nonselective enzyme 
action(s) are the same with either delivery approach. Through conventional delivery, the problem of immuno-
response to an enzyme after repeated administration at proper intervals for a long time prevents its repeated use 
to treat a chronic disease over a long time. For any forms of an enzyme including a native one, the enzyme via 
extracorporeal delivery is not expected to elicit immunoresponse at all after repeated administration at proper 
intervals for a long time and can be expected to have a much longer period of action since every delivery. The 
closed dialysate circuit to circulate a small volume of dialysis solution of the enzyme may also prevent the dialysis 
disequilbrium syndrome and the imbalance of small nutrients/hormones. As a result, a native uricase, which 
cannot be repeatedly administrated at proper intervals for a long time via conventional delivery, may be readily 
administrated via extracorporeal delivery at proper intervals for continued treatment of refractory gout over a 
long time. However, more efforts are needed to prove the effectiveness of extracorporeal delivery to avoid the 
immunoresponse to a therapeutic enzyme after repeated administration at proper intervals for a long time, since 
hemodialysis was difficult to be administrated repeatedly to goose as the model in vivo.
Figure 3. Changes of uric acid with goose as the hyperuricemia model in vivo and uricase pharmacodynamics. 
See legends of Fig. 2 for definitions of symbols and parameters. (a) C1T,i, C2T,i and C3T,i at 0.75 U uricase; (b) SQ1i, 
SQ2i and TQ from data in (a).
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The extracorporeal delivery approach may also be used to deliver macromolecular nonenzyme agents bearing 
selective interactions with unwanted small biochemicals in blood to release indiffusible or nontoxic products, such 
as reactive polymer scavengers that can selectively chelate or scavenge unwanted small biochemicals in the closed 
dialysate circuit. The extracorporeal delivery of such macromolecular nonenzyme agents is absorbing when no 
suitable enzymes are available, and can make artificial kidneys more favorable because of no burden on kidney 
excretion of enzyme products. Moreover, with a group of enzymes and/or macromolecular nonenzyme agents, 
multiple unwanted circulating small biochemicals can be removed concomitantly, and/or an unwanted small sub-
strate can be converted into nontoxic product(s) via consecutive reactions, to advance artificial livers. Notably, as 
for the effective treatment of refractory gout, the use of high activity of uricase in the closed dialysate will produce 
a large quantity of hydrogen peroxide that will easily diffuse into blood. The toxicity of uricase product hydrogen 
peroxide is a problem for the treatment of refractory gout with uricase, which is more pronounced with patients 
bearing glucose-6-phosphate dehydrogenase deficiency. However, clearly, catalase whose activity is in great excess 
to that of uricase can be co-administrated in the closed dialysate to eliminate hydrogen peroxide, and meanwhile 
to regenerate free oxygen molecule in the closed dialysate to promote the action of the delivered uricase. The phar-
macological efficacy and safety for the removal of blood uric acid by the co-administration of uricase and catalase 
through extracorporeal delivery are incomparable advantages over any conventional delivery. Furthermore, the 
device for extracorporeal delivery of therapeutic enzymes and macromolecular nonenzyme agents can be minia-
turized to develop novel portable artificial kidney/livers for their uninterrupted long-term actions when such thera-
peutic macromolecular agents are supplemented at proper intervals, but molecular-adsorbent-recirculating-system 
cannot be miniaturized due to the consumption of dialysis solution20,21. Therefore, the extracorporeal delivery 
approach is promising for effective delivery of therapeutic enzymes and macromolecular nonenzyme agents to 
remove unwanted circulating small biochemicals causing/deteriorating chronic diseases.
Methods
Geese were purchased from Guang’an Langde Goose Co. Ltd. (Guang’an, Sichuan, China, http://www.qy6.com/
qyml/compuser8231.html), and braised in the Laboratory Animal Center of Chongqing Medical University under 
sanitary conditions. All experimental operations with geese were as gentle as possible to minimize suffering; all 
personnel involved in experimental operation with geese got the licenses from the Laboratory Animal Center 
of Chongqing Medical University. After treatment with the delivered uricase, geese were further braised under 
the same conditions after careful handling of wounds/cuts. This work was approved by the Ethical Commission 
of Chongqing Medical University; all the experimental methods involving geese were in accordance with the 
guidelines of the Animal Care and Use Committee of Chongqing Medical University; all experimental protocols 
involving geese were approved by the Animal Care and Use Committee of Chongqing Medical University.
Recombinant expression of the bacterial uricase was completely the same as reported previously11,12,16–18. 
Uricase activity was determined with 75 μ M uric acid in sodium borate buffer at pH 7.4 by absorbance at 293 nm; 
one unit oxidizes one micromole substrate per min14–16. Blood was centrifuged at 3000 g for 10 min to get plasma. 
Each dialysate sample was immediately acidified with final 5% HClO4, and then neutralized with saturated 
K2HPO4 to get supernatant. Uric acid in plasma or supernatant of the dialysate was determined by a direct kinetic 
uricase method resistant to both hydrogen peroxide and reversible uricase inhibitors22. Other details of analysis 
were provided in Supplementary Note S2.
The dialysis buffer at pH ~7.3 was 10 mM sodium phosphate and 0.9% NaCl plus 27.0 g/L BSA (BSA seques-
ters free molecule of uric acid to facilitate its diffusion). The blood circuit in the dialyzer plus the connecting tubes 
has a capacity of about 28 ml and the capacity of the closed dialysate circuit was about 20 ml, but the capacity of 
the closed dialysate circuit was uncontrollable due to free diffusion of water and small solutes across the dialyzer 
membranes. Sodium heparin was used to prevent coagulation of blood. For the normal physiological states of 
geese in 8 h (no signs of salivation, lacrimation, tremors and gasping), the blood circuit was run at no more than 
15 ml/min while the closed dialysate circuit was run at 20 ml/min to make homogenous solution. After the two 
circuits of the delivery device was run for an indicated time to achieve the equilibrium of uric acid, the native 
uricase in no more than 1.5 ml sterile dialysis buffer was added directly into the closed dialysate circuit.
For the removal of uric acid with hyperuricemia models in vitro, 200 ml fresh blood from one goose was 
placed in a glass of 500 ml to serve as the blood reservoir, which was magnetically stirred at 37 °C in water-bath 
in an isolated small room air-conditioned at 25 °C. The blood circuit was connected to the blood reservoir while 
30 ml sterile dialysis solution was added to the closed dialysate circuit. All hyperuricemic blood models in vitro 
had uric acid from 0.40 to 0.80 mM. Uric acid reached equilibrium in the two circuits after running of the delivery 
device alone for 20.0 min (Supplementary Data S3). After continuous running of the delivery device alone for 
30 min, 0.30 U uricase, 0.75 U uricase, or no uricase, in 1.50 ml sterile dialysis buffer was added directly into the 
closed dialysate circuit. After further running of the device for an indicated period since the addition of uricase, 
blood of 0.8 ml before and after the dialyzer, and the dialysate of 0.20 ml from the closed dialysate circuit, were 
sampled with a special order for analyses (Supplementary Note S1 and Note S2).
Geese of body weight over 5.0 kg and blood uric acid from 0.40 to 0.80 mM served as hyperuricemia models 
in vivo. Experiments were performed in an isolated small room air-conditioned at 25 °C and geese were kept in 
the room for more than 2 h before operation. The blood circuit was connected to goose artery and vein according 
to standard procedure of hemodialysis. The wings and legs of goose were tied with wide bandages to a frame to 
restrain its activity but provide the maximum comfort. After running of the delivery device alone for 50~60 min, 
no uricase as the control, the native uricase of 0.15 U per kg goose body weight, the native uricase of 0.30 U per kg 
goose body weight, or the native uricase of 0.45 U per kg, in 1.50 ml sterile dialysis buffer, was added into the 
closed dialysate circuit. After further running of the delivery device plus the delivered uricase for an indicated 
period, blood of 0.80 ml before and after the dialyzer and the dialysate of 0.20 ml were sampled with a special 
order for processing and analyses (Supplementary Note S1 and Note S2).
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